Ritedose Boosts Production Capacity with New Syntegon Packaging Line for COPD Drug Ohtuvayre

Ritedose Expands Manufacturing with New Syntegon Line

In a strategic move to meet the increasing demand for individually packaged vial medications, The Ritedose Corporation, Inc. has recently announced the addition of a seventh packaging line from Syntegon at their manufacturing facility. This exciting development is particularly aimed at bolstering the production of the newly approved COPD medication, Ohtuvayre, among other key products.

Enhancing Production Capacity

Ritedose, recognized as the largest contract development and manufacturing organization (CDMO) in the United States, specializes in sterile Blow-Fill-Seal (BFS) production for unit dose solutions targeted at both ophthalmic and respiratory markets. The introduction of this new Syntegon line is projected to double the company’s current packaging capacity, enabling the execution of between 160 million and 170 million vials per year.

This significant boost in production capability highlights Ritedose’s commitment to efficient and flexible manufacturing processes that address the evolving needs of healthcare providers and patients.

Meeting Market Demands

The new Syntegon packaging system is set to play a pivotal role in Ritedose's endeavors to support Verona Pharma’s innovative COPD drug, Ohtuvayre. This medication is particularly noteworthy as the first inhaled product incorporating a novel mechanism of action approved in over two decades. Ritedose officially became the manufacturing partner for Verona in September 2024, emphasizing a collaborative effort to advance healthcare solutions.

“In our pursuit of excellence, Ritedose consistently invests in expanding manufacturing capabilities,” said Jody Chastain, President and CEO of Ritedose. “This latest addition will not only enhance our collaboration with Verona Pharma but will also prepare us to meet the demands of various disease states requiring individually packaged vial medications.”

Commitment to Quality and Safety

For more than 20 years, Ritedose has relied on Syntegon Technology to deliver cutting-edge processing and packaging solutions. The new automated system is designed specifically for the secondary packaging of pharmaceutical and consumer goods, allowing Ritedose to maximize output while minimizing waste, which underscores their dedication to patient safety and quality assurance.

The packaging line is currently undergoing Site Acceptance Testing at Ritedose's facility and is expected to be operational by early summer 2025. As the healthcare landscape continues to evolve, this expansion signifies Ritedose's proactive approach to sustaining high-quality production standards.

Ritedose's Legacy

The Ritedose Corporation has built a reputation for excellence by guiding the development of pharmaceuticals from clinical trials to commercialization. With a strong focus on quality and patient outcomes, Ritedose partners with leading pharmaceutical companies to improve healthcare delivery and patient outcomes. Their commitment to innovation and customer satisfaction sets them apart as a leader in the industry.

As the world of healthcare continues to transform, Ritedose remains steadfast in its mission to provide reliable medications and enhance patient experiences through high-quality manufacturing practices. For further information about Ritedose and their latest advancements, visit Ritedose.com.